Duke Researchers Pivot to Attack the New Coronavirus
Everything Duke experts have learned over the years about the spread of new diseases, the biology of viruses, and the techniques of developing treatments and vaccines is now being applied to the new coronavirus, SARS-CoV-2, and the illness it causes, COVID-19.
Duke joins first national effort to test a potential COVID-19 therapy
Duke University Hospital has joined the first national study to test a potential therapy for COVID-19, giving hospitalized adult patients with significant symptoms an option to participate.
'We can control the outbreak': Duke infectious disease doctor says COVID-19 situation will get worse before it gets better
A Duke University professor of medicine and global health has been studying emerging infections for his entire career but has yet to see anything capture the attention of society quite like this.
Duke's Corona Virus Response
Officials at Duke, along with health officials worldwide, are monitoring an outbreak of pneumonia caused by a novel (new) coronavirus that originated in late 2019. We are not aware of any 2019 novel coronavirus (COVID-19) cases at any Duke campus or facility. We are providing this information to raise awareness and inform the Duke community.
Why a coronavirus vaccine is more than a year away, despite medical researchers' progress
As the coronavirus spreads, deaths mount and fears grow across the globe, biotech companies, universities and government agencies scramble – some together, others alone – for a vaccine to contain it.
A Bold Choice
When a Duke-led research team won a $300 million federal grant to help develop an AIDS vaccine in 2005, the global situation was looking grim.
The Lancet Commentary: Shortening HIV vaccine regimens to achieve high coverage
An international commission of global experts convened by the International AIDS Society and The Lancet in 2018 advised that to eliminate HIV, global treatment efforts should be complemented by a robust scale-up in primary HIV prevention, including the development of a preventive vaccine.
Study supports safety of simultaneous IIV4, PCV13 and DTaP vaccinations in young children
The CDC’s Immunization Safety Office, Duke Human Vaccine Institute and Kaiser Permanente Vaccine Study Center conducted a clinical study, funded by the CDC’s Clinical Immunization Safety Assessment (CISA) Project, to assess whether the risk of fever, and potentially febrile seizure, might be reduced by administering the quadrivalent inactivated influenza vaccine (IIV4) separately from the pneumococcal (PCV13) and diphtheria-tetanus-pertussis (DTaP) vaccines.
Researchers at Duke's Human Vaccine Institute are leading research aimed at developing vaccines
Take a moment to watch the Duke Health Live Video Series.
Immune System Can be Coaxed into Selecting Key Antibodies to Fight HIV
Researchers have cleared a major obstacle in the development of an HIV vaccine, proving in animal models that effective, yet short-lasting antibodies can be coaxed into multiplying as a fighting force against the virus.